Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Table 8 Relationship of biomarker level changes to changes in ADCOMS scores at week 22 compared to baseline

Cohort	Subject	AD Severity Stage	ADCOMS score CFB	Biomarkers CFB
Cohort	Subject	AD Severity Stage	ADCOMS score CFB	Aβ-42	Aβ-42/40	Tau (total)	Tau (pT181)	Tau (pT217)	α-Synuclein	GFAP	YKL-40	NfL
1	002	moderate	I	D	D	I	D	D	I	I	I	I
	003	moderate	N	I	I	I	I	I	D	I	D	I
	004	mild	I	I	I	I	I	I	I	D	I	I
	005	mild	D	D	D	D	D	D	D	D	I	D
2	006	severe
	007	mild	N	D	I	I	I	I	I	I	D	I
	011	mild	N	I	I	D	D	D	D	D	D	D
3	012	severe
	014	moderate	D	D	D	D	D	D	D	D	D	I
	015	mild	N	D	D	D	D	D	D	D	D	I
Percent of subjects with stable/ decrease in ADCOMS with positive^a biomarker changes				33.3	50.0	66.7	66.7	66.7	83.3	66.7	83.3	33.3

CFB Change from baseline, N No change from baseline, I Increase from baseline, D Decrease from baseline
^aA positive biomarker change is an increase for Aβ-42, Aβ42/Aβ40 ratio and a decrease for all other markers
No ADCOMS available for subject 006 and no biomarkers available for subject 012 at week 22

ISSN: 1758-9193